2015 American Transplant Congress
Pediatrics & Donor Derived Disease Transmission: The US OPTN Experience
Potential donor derived disease transmission events (PDDTE) are tracked by the OPTN DTAC. Specific evaluation of potential transmissions from pediatric (ped) donors or the impact…2015 American Transplant Congress
Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias
INTRODUCTION:The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic…2015 American Transplant Congress
Multicenter Study to Develop a Novel Prediction Index for Hepatocellular Carcinoma (HCC) Recurrence After Liver Transplant (LT)
1UCSF, San Francisco, CA; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Jacksonville, FL.
Several factors have been associated with a high risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), but no reliable risk score has…2015 American Transplant Congress
Detecting Bowel Cancer in Pre-Dialysis, Dialysis Patients and Kidney Transplant Recipients – The DETECT Study
University of Sydney, Sydney, NSW, Australia.
Background: Colorectal cancer (CRC) is the third most common solid organ cancer in people living with kidney disease, and has a very poor prognosis, with…2015 American Transplant Congress
Donor-Derived Tumor Transmission Events. A Summary of 2008-2013 Data from the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
Purpose: Transmission of donor malignancy via transplantation is an uncommon but significant occurrence. The OPTN Disease Transmission Advisory Committee (DTAC) has monitored such complications since…2015 American Transplant Congress
Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death
We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…2015 American Transplant Congress
Allo-Stimulated Interferon-γ Release and Natural Killer Cell Function Defines and Risk Stratifies Cancer Development in Kidney Transplant Recipients Who Have Cancer Post-transplantation
Reducing immunosuppression is efficacious in primary prevention of cancer in Kidney Transplant Recipients (KTR) but can precipitate graft rejection. Conventional immunosuppressive drug monitoring fails to…2015 American Transplant Congress
Early Detection of HCC Mutations in Indeterminate Lesions Using Liquid Biopsies
Background Recent sequencing efforts have characterized the mutation profile of hepatocellular carcinoma (HCC); however, the relevance to clinical decision-making has been limited by the infrequency…
American Transplant Congress abstracts